Suppr超能文献

一种分层肽-镧系元素框架,可准确纠正细胞内致癌蛋白-蛋白相互作用。

A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction.

机构信息

Frontier Institute of Science and Technology, Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology , Xi'an Jiaotong University , Xi'an 710054 , China.

The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710061 , P.R. China.

出版信息

Nano Lett. 2019 Nov 13;19(11):7918-7926. doi: 10.1021/acs.nanolett.9b03028. Epub 2019 Oct 31.

Abstract

Intracellular protein-protein interactions (PPIs) are a vital and yet underexploited class of therapeutic targets for their crucial roles in cellular processes and involvement in disease initiation and progression. Although some successful chemistry and nanotechnologies have been introduced into peptide PPI modulators to allow cell and tissue permeability, significant challenges remain with regard to the efficient and precise modulation of PPIs within specific cells of diseased tissues, such as solid tumors. Herein, an intratumoral transformable hierarchical framework, termed iPLF, was fabricated via a two-step self-assembly between peptides and lanthanide-doped nanocrystals. In this proof-of-concept study, using NanoEL effect, TME response, and tumor marker targeting, iPLF in vivo delivered the p53-MDM2 modulator PMI into tumor cells and β-catenin-Bcl9 modulator Bcl9 into tumor stem cells. This crafted programmed nanomedicine with triple-stage delivery and responsiveness accurately modulated the specific intracellular protein-protein interactions, resulting in the suppression of tumor growth and metastasis in vivo, while maintaining a highly favorable safety profile. iPLF reached the goal of accurate, potent, and hazard-free intracellular PPI modulation, thereby providing a means to improve current knowledge of PPI networks and a novel therapeutic strategy for a great variety of diseases.

摘要

细胞内蛋白质-蛋白质相互作用 (PPIs) 是一类重要但尚未得到充分利用的治疗靶点,因为它们在细胞过程中起着关键作用,并参与疾病的发生和发展。尽管已经将一些成功的化学和纳米技术引入到肽 PPI 调节剂中,以允许细胞和组织通透性,但在特定疾病组织的细胞中有效且精确地调节 PPIs 方面仍然存在重大挑战,例如实体瘤。在此,通过肽和镧系掺杂纳米晶体之间的两步自组装,构建了一种名为 iPLF 的肿瘤内可转化的层次结构框架。在这项概念验证研究中,使用 NanoEL 效应、TME 反应和肿瘤标志物靶向,iPLF 将 p53-MDM2 调节剂 PMI 递送到肿瘤细胞中,并将 β-连环蛋白-Bcl9 调节剂 Bcl9 递送到肿瘤干细胞中。这种具有三重递药和响应能力的定制程序化纳米药物准确地调节了特定的细胞内蛋白质-蛋白质相互作用,从而抑制了体内肿瘤的生长和转移,同时保持了高度有利的安全性。iPLF 达到了准确、强效和无危险的细胞内 PPI 调节的目标,从而为改善当前对 PPI 网络的认识和为各种疾病提供了一种新的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验